UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Pharmacyclics

In a report published Friday, Wedbush Securities reiterated its Outperform rating on Pharmacyclics PCYC, and raised its price target from $55.00 to $93.00. Wedbush noted, “Importantly, the change from an ‘incidence-based' model for oncology drugs to a ‘prevalence-based' model is associated with large increases in market opportunities, as we have seen with Gleevec ($4.7B in 2011 sales in chronic myelogenous leukemia, CML). As median PFS for ibrutinib-treated CLL patients enrolled in clinical trials continues to increase, we expect the Street's appreciation of the drug's potential also to increase. Another comparator, we note, Revlimid sales are on a ~$4B run-rate. It is indicated for use in multiple myeloma, an indication with 40% lower prevalence. Industry sources indicate that Revlimid has a ~50% overall market share (more than our 30% iburtinib share estimate), with an average duration of use of ~13 months (less than the likely 18 month+ PFS for ibrutinib in CLL).” Pharmacyclics closed on Thursday at $65.59.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetReiterationAnalyst RatingsWedbush Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!